Renee Tannenbaum
Direktor/Vorstandsmitglied bei CARDIFF ONCOLOGY, INC.
Vermögen: 1 Mio $ am 30.04.2024
Profil
Dr. Renee P.
Tannenbaum is an Independent Director at ANI Pharmaceuticals, Inc. and an Independent Director at Cardiff Oncology, Inc. She is on the Board of Directors at ANI Pharmaceuticals, Inc. and Cardiff Oncology, Inc. Dr. Tannenbaum was previously employed as a Vice President-Global Partnering by Halozyme, Inc., an Independent Director by Zogenix, Inc., a Head-Global Customer Excellence by AbbVie, Inc., an Independent Director by Sharps Compliance Corp., a President by Myrtle Potter & Co. LLC, a Chief Commercial Officer & Executive VP by Elan Pharmaceuticals, Inc., and a Professor by University of the Sciences in Philadelphia.
She also served on the board at Nordic Nanovector ASA, Cipher Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd.
and The Bay Area Bioscience Association.
She received her undergraduate degree from the University of Connecticut, an MBA from Temple University (Pennsylvania), a doctorate degree from the University of Connecticut and a doctorate degree from Philadelphia College of Pharmacy.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 16.05.2024 | 18 211 ( 0,09% ) | 1 Mio $ | 30.04.2024 | |
CARDIFF ONCOLOGY, INC.
0,02% | 22.04.2024 | 10 000 ( 0,02% ) | 39 900 $ | 30.04.2024 |
Aktive Positionen von Renee Tannenbaum
| Unternehmen | Position | Beginn |
|---|---|---|
| CARDIFF ONCOLOGY, INC. | Direktor/Vorstandsmitglied | 10.06.2021 |
| ANI PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 22.03.2022 |
Ehemalige bekannte Positionen von Renee Tannenbaum
| Unternehmen | Position | Ende |
|---|---|---|
| ZOGENIX, INC. | Direktor/Vorstandsmitglied | 07.03.2022 |
Halozyme, Inc.
 Halozyme, Inc. BiotechnologyHealth Technology Part of Halozyme Therapeutics, Inc., Halozyme, Inc. is a company based in San Diego, CA. | Corporate Officer/Principal | 01.07.2021 |
| THOR MEDICAL | Direktor/Vorstandsmitglied | 12.10.2016 |
| CIPHER PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 09.08.2016 |
| ABBVIE INC. | Corporate Officer/Principal | 01.01.2016 |
Ausbildung von Renee Tannenbaum
| University of Connecticut | Doctorate Degree |
| Temple University (Pennsylvania) | Masters Business Admin |
| Philadelphia College of Pharmacy | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ABBVIE INC. | Health Technology |
| CIPHER PHARMACEUTICALS INC. | Health Technology |
| CARDIFF ONCOLOGY, INC. | Health Technology |
| ANI PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Sharps Compliance Corp.
 Sharps Compliance Corp. Miscellaneous Commercial ServicesCommercial Services Sharps Compliance Corp. engages in the provision of healthcare waste management services including medical, pharmaceutical, and hazardous. It focuses on developing management solutions for medical waste and unused dispensed medications generated by small and medium quantity generators. The company was founded in November 1992 and is headquartered in Houston, TX. | Commercial Services |
| The Bay Area Bioscience Association | Health Technology |
Immune Pharmaceuticals Ltd.
 Immune Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Immune Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd. develops pharmaceutical products for the treatment of cancer and pain. The company is based in Herzliya-Pituach, Israel. Immune Pharmaceuticals was acquired by EpiCept Corp. on August 26, 2013 for $21.43 million. | Health Technology |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
Elan Pharmaceuticals, LLC
 Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Health Technology |
Myrtle Potter & Co. LLC
 Myrtle Potter & Co. LLC Miscellaneous Commercial ServicesCommercial Services Myrtle Potter & Co. LLC provides life science and healthcare consulting services. The private company is based in San Jose, CA. The company was founded by Myrtle S. Potter. | Commercial Services |
Halozyme, Inc.
Halozyme, Inc. BiotechnologyHealth Technology Part of Halozyme Therapeutics, Inc., Halozyme, Inc. is a company based in San Diego, CA. | Health Technology |
